北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学药学院  > 期刊论文
学科主题: 药学
题名:
The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: A meta-analysis from randomized controlled clinical trials
作者: Zhao, Y. L.1; Han, S.2,3; Pu, R.4; Shi, L. W.1,3
关键词: Docetaxel ; gefitinib ; meta-analysis ; NSCLC
刊名: INDIAN JOURNAL OF CANCER
发表日期: 2014-03-01
DOI: 10.4103/0019-509X.154070
卷: suppl.3, 期:7, 页:86-91
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
关键词[WOS]: PHASE-III TRIAL ; PLATINUM-BASED CHEMOTHERAPY ; PERFORMANCE STATUS ; MUTATIONS ; MORTALITY ; THERAPY ; QUALITY ; CHINA
英文摘要:

Background: The extent of the benefit of gefitinib in the treatment of advanced nonsmall-cell lung cancer (NSCLC) is till controversial, when compared with docetaxel. We performed this meta-analysis to compare the efficacy and toxicity of gefitinib with docetaxel for different patients with advanced NSCLC. Materials and Methods: We searched PubMed, Cochrane Library, and identified 5 randomized controlled clinical trials published within 2000-2013. After further full-text screening, 4 clinical trials were included in the final meta-analysis. Results: The outcomes of treatment efficacy included progression-free survival (PFS), overall survival (OS) and objective response rate (ORR). Comparing gefitinib to docetaxel for advanced NSCLC patients, the pooled hazard ratio (HR) of PFS was 0.91, (95% confidential index [CI] = 0.83-0.99), the pooled HR of OS was 1.02, (95% CI = 0.93-1.13), the pooled risk ratio of ORR was 1.57, (95% CI = 1.01-2.47). Conclusions: Gefitinib was found to significantly improve patients PFS and response rate compared with docetaxel. There is no difference of OS between gefitinib and docetaxel.

语种: 英语
WOS记录号: WOS:000352281900005
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/57373
Appears in Collections:北京大学药学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Sch Publ Hlth, Beijing 100191, Peoples R China
2.China Natl Ctr Biotechnol Dev, Beijing 100039, Peoples R China
3.Peking Univ, Sch Pharmaceut Sci, Beijing 100191, Peoples R China
4.Peking Univ, Int Res Ctr Med Adm, Beijing 100191, Peoples R China

Recommended Citation:
Zhao, Y. L.,Han, S.,Pu, R.,et al. The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: A meta-analysis from randomized controlled clinical trials[J]. INDIAN JOURNAL OF CANCER,2014,suppl.3(7):86-91.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhao, Y. L.]'s Articles
[Han, S.]'s Articles
[Pu, R.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhao, Y. L.]‘s Articles
[Han, S.]‘s Articles
[Pu, R.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace